BofA lowered the firm’s price target on Sarepta (SRPT) to $179 from $210 and keeps a Buy rating on the shares. Following the news of the departure of Peter Marks from the FDA’s Center for Biologics ...

The decline in biotech stocks comes after FDA official Peter Marks' resignation, citing irreconcilable differences with the ...

Biotech stocks plunge after Dr. Peter Marks resigns from FDA, citing disputes with RFK Jr. over vaccines and drug approvals.

Shares of biotech company Sarepta Therapeutics (NASDAQ:SRPT) fell 10.8% in the afternoon session after RBC analyst Brian ...

Peter Marks, who played a key role in U.S. President Donald Trump's first term in developing COVID-19 vaccines, will leave ...

RBC Capital analyst Brian Abrahams downgraded Sarepta (SRPT) to Sector Perform from Outperform with a price target of $87, down from $161. The ...

Mizuho Securities analyst Uy Ear maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report) today and set a price target of ...

We recently published a list of the 10 Best Mid Cap Biotech Stocks to Buy. In this article, we are going to take a look at ...

CHICAGO -- Semaglutide further solidified its efficacy for diabetes-associated cardiovascular conditions, this time building ...

Listed below are links to the GEN stories reference in this episode of Touching Base Gene Therapy Tested in Mice Offers New ...

Sarepta Therapeutics announced that a patient with Duchenne muscular dystrophy who received Elevidys (delandistrogene moxeparvovec-rokl) died following treatment.

The patient died of acute liver failure; the maker of the gene therapy noted that the patient also had a recent ...